Transcendence Age Corp. Acquires 19.9% Ownership of Vics Consulting Group Inc., a CBD Farm Contractor

0
29

Granada Hills, California–(Newsfile Corp. – April 19, 2021) – Pervasip Corp. (OTC Pink: PVSP) is pleased to announce that its wholly owned subsidiary Transcendence Age Corp. (“Transcendence”) has acquired a 19.9% equity stake in Vics Consulting Group Inc. (“Vics”). Vics is a California-based company that received a contract to build a state-of-the-art CBD farm in Uzbekistan to grow and distribute CBD products to the European and Asian markets.

“We were drawn to Transcendence because of the full-service role their team plays in the international arena,” said Kyong Lae Kim, CEO and founder of Vics. “Some of their team members have built roads, runways, irrigation systems, farms, and greenhouses, while other team members have created the seeds and medical studies for a robust indoor and outdoor crop.”

Mr. Kim continued, “Twenty companies traveled to Uzbekistan to bid on a colossal self-sustaining farming project. Vics received the contract primarily due to the experience and know-how of the Transcendence representatives that accompanied me, which included experience building military bases overseas. We intend to set the standard for the build-out of a large-scale CBD production facility in Uzbekistan, and to bring this model to my contacts throughout Asia.”

Cesar Herrera, President of Transcendence, said, “We plan to work closely with the Uzbekistan government to assist with the creation of legislation pertaining to the growth, farming, and processing of CBD. We believe we can avoid the past mistakes U.S. farmers made in establishing CBD farms. Because of Uzbekistan’s infancy stage, it puts us in a strategic position to develop the infrastructure as well as the sustainable farming required to reap the benefits of controlled large-scale production.”

Vics is at the forefront of expanding the CBD market throughout Asia. Mr. Kim works with bio-labs in South Korea and has studied CBD for the past five years. Vics is in the process of registering with the Korean FDA for psilocybin research, which it intends to combine with the five-year CBD study. Vics and Transcendence share revenues and expenses on a project-by-project basis.

About Pervasip Corp.

Pervasip formed Transcendence to study and provide health and wellness consulting for psilocybin treatments. Research has shown that psilocybin has potential to treat a wide range of behavioral and psychiatric disorders. Transcendence is comprised of an established team of professionals, incorporating infrastructure specialists, growing specialists, and holistic medicinal specialists. Several of its team members also have an expertise in a variety of CBD products.

For further details regarding the company, please refer to the information on our web sites at www.pervasip.net and transcendenceagecorp.com.

Please email Investor Relations with any questions at info@pervasip.net or call 855-464-2535 extension 1.

The information contained herein includes forward-looking statements. These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/80789

LEAVE A REPLY

Please enter your comment!
Please enter your name here